| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Epidemiology Biomarkers & Prevention, Vol 1, Issue 6 475-479, Copyright © 1992 by American Association for Cancer Research
ARTICLES |
S Zucker, RM Lysik, MH Zarrabi, W Stetler-Stevenson, LA Liotta, H Birkedal-Hansen, W Mann and M Furie
Department of Research, Department of Veterans Affairs Medical Center, Northport, New York 11768.
We have developed a sensitive and specific sandwich-type enzyme-linked immunosorbent assay to detect M(r) 72,000 type IV collagenase [matrix metalloproteinase 2 (MMP-2)] in human plasma. As a result of the linkage between MMP-2 production by cancer cells and the metastatic phenotype, we undertook this study to compare plasma MMP-2 levels in healthy individuals, patients with various types of cancer, and hospitalized patients with chronic diseases other than cancer. The results demonstrate that MMP-2 levels are not increased in cancer patients regardless of the extent of disseminated malignancy. In an effort to explain this data, we compared MMP-2 secretion by human umbilical vein endothelial cells and lung cancer cells passaged as cell lines. Endothelial cells secreted higher levels of MMP-2 than did lung cancer cells propagated in vitro. We propose that blood vessel lining cells make a sizable contribution to plasma levels of MMP-2 and may thereby obfuscate the detection of increased levels of MMP-2 originating from extravascular sources such as solid tumors.
This article has been cited by other articles:
|
|
 |
|
  A. Yoshimoto, K. Kasahara, M. Nishio, T. Hourai, T. Sone, H. Kimura, M. Fujimura, and S. Nakao Changes in Angiogenic Growth Factor Levels After Gefitinib Treatment in Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 233 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mannello and M. Sebastiani Zymographic Analyses and Measurement of Matrix Metalloproteinase-2 and -9 in Nipple Aspirate Fluids Clin. Chem., September 1, 2003; 49(9): 1546 - 1550. [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Levitt, F. A. L. M. Eskens, K. J. O'Byrne, D. J. Propper, L. J. Denis, S. J. Owen, L. Choi, J. A. Foekens, S. Wilner, J. M. Wood, et al. Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer Clin. Cancer Res., July 1, 2001; 7(7): 1912 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Rowinsky, R. Humphrey, L. A. Hammond, C. Aylesworth, L. Smetzer, M. Hidalgo, M. Morrow, L. Smith, A. Garner, J. M. Sorensen, et al. Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies J. Clin. Oncol., January 5, 2000; 18(1): 178 - 178. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
